Summary & Overview
HCPCS J0185: Injection, Aprepitant 1 mg
HCPCS Level II code J0185 denotes an injectable formulation of aprepitant billed per 1 mg unit, used as a parenteral antiemetic. This code is relevant nationally for clinicians, infusion centers, and payers managing supportive care for patients receiving emetogenic therapies. Coverage and billing practices for injectable antiemetics affect pharmacy spend, site-of-care decisions, and outpatient infusion workflows. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find an overview of the clinical context for aprepitant injection, common sites of service where the code is used, and the payer landscape that governs coverage and reimbursement. The publication summarizes benchmarks for utilization and cost where available, highlights policy updates that influence billing and payment for injectable antiemetics, and clarifies coding considerations specific to a per-milligram HCPCS Level II drug code. Intended audiences include revenue cycle professionals, practice administrators, and policy analysts seeking a concise reference for J0185 in outpatient infusion and clinic settings. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J0185 represents an injectable formulation of aprepitant, billed per 1 mg unit. The service type is drug administration, reflecting a single-agent antiemetic medication supplied as an injected dose. The typical site of service for this code is outpatient infusion or clinic settings where parenteral antiemetic therapy is provided.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult receiving intravenous antiemetic therapy to prevent chemotherapy-induced nausea and vomiting. The medication J0185 (injection, aprepitant, 1 mg) is administered as part of an antiemetic regimen before or during moderately to highly emetogenic chemotherapy or for postoperative nausea prevention when aprepitant injectable formulation is used. The clinical workflow: a chemotherapy or surgical patient is assessed by the oncology or perioperative nursing team; orders for an injectable aprepitant dose are placed in the electronic medical record; pharmacy prepares the unit dose; nursing verifies patient identity, allergy status, and infusion access; the medication is administered intravenously or via existing central line or peripheral IV prior to chemotherapy infusion or at induction of anesthesia; the patient is monitored for adverse reactions for the facility standard observation period; administration documentation is recorded in the medical record and the billing charge for J0185 is submitted with applicable diagnosis and modifier information.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JZ | Drug not administered to the patient | Use when aprepitant was prepared but not administered. |